3rd ESTRO Forum 2015 S623 squamous cell carcinoma of the head and neck (SCCHN) who are treated with combined chemoradiation (CRT). The aim was to find a potential SUV max threshold to predict risk of distant failure (DF), local failure (LF) and regional failure (RF). This may help identifying patients at risk and subject them to intensified treatment.
Purpose/Objective: Tumor hypoxia is commonly related to a poorer prognosis and to higher radioresistance. The degree of reoxygenation during radiotherapy contributes to improved therapy success. 18-Fluoromisonidazole PET/CT (FMISO-PET) non-invasively allows visualizing tumor hypoxia and its dynamics under chemoradiation (CRT) of squamous cell cancer of the head and neck (SCCHN). There is little evidence for the relation between hypoxia and changes in blood oxygenation determined by hemoglobin (HB) and erythropoietin (EPO) levels in blood. Matter of interest is also the relation between these biomarkers with metastasis-free survival (MFS) and loco-regional control (LRC). Materials and Methods: Between 2008 and 2014 we prospectively analyzed the dynamics of tumor hypoxia during CRT in 21 patients at our center. This consisted of radiotherapy in IMRT-technique (5 x 2 Gy/week up to 70 Gy) and concomitant platinum-based chemotherapy (weeks one, four and seven). Additionally the patients received pretreatment FDG-PET and MRI scans of the head and neck and FMISO-PET for hypoxic imaging (in week 'zero'). The hypoxia was further evaluated in week 2 and 5 with two more FMISO-PET scans. EPO and HB levels were also determined parallel to hypoxic imaging. Tumor hypoxia in FMISO-PET was defined as SUV max (tumor)/SUV mean (muscle). In follow-up (FU) we performed regular CT and MRI scans of the head and neck and lung. For correlation analysis we used Spearman coefficient. We performed statistical analysis with SPSS Statistics 21 (IBM). Results: Between 08/2008 and 04/2014, 22 patients (three women and nineteen men) with histologically proven SCCHN were recruited, mean ECOG score 1, average FU time was 30.6 months (0.6-63 months). 4 patients developed DF (18.2 %). Average SUV max (tumor)/SUV mean (muscle) was 1.9/1.6/1.3 (weeks 0/2/5; n=22/20/17). Average SUV max in FDG-PET was 14.4 (n=20). Average HB-concentrations were 14.1/12.6/10.9 g/dl (weeks 0/2/5). Average EPO-concentrations were determined in 9 patients (7.3 mU/ml). Correlation coefficient between DF and FMISO-SUV max (tumor)/SUV mean (muscle) is -0.3/-0.4/-0.4 (in weeks 0/2/5). Correlation coefficient between HB and EPO, and between HB and FMISO is -0.02 and 0.02/-0.3/-0.4 (weeks 0/2/5), respectively. Conclusions: There could not be shown any significant correlation between tumor hypoxia and HB and/or EPO, nor were there any correlations between distant failure and SUV max (tumor)/SUV mean (muscle). There is need for further data acquisition. Purpose/Objective: In cases of head and neck cancer (HNC) radiotherapy, custom-designed oral prostheses are sometimes used to depress the tongue or push the hard palate away from the clinical target volume (CTV) and intended to reduce side-effects to surrounding organs at risk (OAR). We evaluated whether the use of custom-designed oral prostheses improved daily setup precision of HNC.
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Materials and Methods:
The custom-designed oral prostheses were made of resin to fit each patient's oral cavity. The upper and lower parts and inter-space bar of the prostheses mate together by occlusal pressure to immobilize and displace the hard palate or tongue to reduce unnecessary radiation dose. Nine locally advanced HNC patients (prostheses group) at our hospital were treated from June 2012 to September 2013 by three-dimensional external radiotherapy using custom-designed oral prostheses, immobilized with a thermoplastic mask. These patients (oropharyngeal: 4; tongue: 3; and maxillary: 2; histologically, 7 squamous cell carcinoma (SqCC), and 2 lymphomas) received total doses of 50.4 to 68.4Gy (mean 58.8Gy) in daily fractions of 1.8 to 2.0 Gy. The seven patients with SqCC received concurrent chemotherapy of CDDP and 5-FU. Each patient's daily setup error was calculated as corrected shift distance by orthogonal electronic portal imaging device (EPID) and the target point marker on the thermoplastic mask. Each patient's average of daily setup error size of medial-lateral (x), anterior-posterior (y) and cranial-caudal (z) axes was compared with that of 21 HNC patients (nonprotheses group) who did not use custom-designed oral prostheses during the same period. The non-prostheses group ( pharyngeal: 11; oral cavity: 3; larynx: 3; thyroid: 2; and salivary gland: 2; histologically, 15 SqCC, 4 adenocarcinomas, and 2 lymphomas) received total doses of 45 to 70.0 Gy (mean 60.4 Gy) in fractions of 1.8 to 2.0 Gy per day. 18 of these patients (excepting 1 adenocarcinoma and 2 lymphomas) received concurrent chemotherapy. Results: All patients tolerated the treatment, although they experienced grade 2 to 3 microsites, dermatitis and leukocytopenia. The average daily setup error for each prostheses group patient was less than that for the nonprostheses group ( (x); 0.8 mm vs. 1.4 mm, (y); 0.7 mm vs.1.0mm, and (z); 0.8 mm vs. 1.3mm, respectively). Mean of (x) error with oral prostheses patients showed a significant difference (p=0.03). In addition, 3D-displacement (mean of sum squares of x, y, z) of prostheses group patients was less than that of non-prostheses group (5.0 vs.9.5, p=0.01).
Conclusions: Custom-designed oral prostheses are selfwearable safe devices. Use of custom-designed oral prostheses in HNC patients can reduce unnecessary radiation to OAR, and also provide better daily setup. More detailed evaluation in a larger patient population is desired in the future. Purpose/Objective: A prospective trial investigated feasibility of a three-phase adaptive radiotherapy scheme using 18F-FDG-PET-CT guided dose-painting-by-numbers (DPBN) IMRT for head-and-neck cancer. We previously reported feasibility and clinical results upto 3 months. We now report on long-term locoregional (LRC) and distant control, overall survival (OS) and late toxicity.
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Materials and Methods:
Ten patients with squamous cell carcinoma of the head and neck received primary radio(chemo)therapy using DPBN. All patients received 3 consecutive phases of 10 fractions for in total 6 weeks. 18F-FDG-PET-CT guided DPBN was planned beteen 2.0 -3.5 Gy per fraction to the GTV (fractions 1-10) and 2.0-2.5 Gy (fractions 11-30). The elective neck was treated at 2.0 Gy/fraction (fractions 1-20). Repeated 18F-FDG-PET-CT after fractions 8 and 18 were used to plan phase 2 and 3, respectively. Concomitant cisplatin at days 1-22-43 at 100 mg/m² was prescribed in 4 patients. All patients underwent multidisciplinary assessment of disease control and late toxicity at months 1-3-6-9-12-16-20-24-30-36 after treatment. We analysed local, regional and distant control and survival; for toxicity evaluation we analysed all grades of late dysphagia, xerostomia and mucosal integrity problems as well as any other grade ≥ 3 late toxicity at 6, 12, 24 and 36 months.
Results:
Patient and tumor characteristics can be found in Table 1. 
